NCT01894360View on ClinicalTrials.gov

A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 14, 2013

Primary Completion Date

May 13, 2014

Study Completion Date

May 13, 2014

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

Belimumab 200 mg/mL

Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.

Trial Locations (1)

66211

GSK Investigational Site, Overland Park